Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-10RB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-10RB ECD-Fc Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. HEK293 Expressed for native glycosylation. |
View IL10RB Products |
| Gene Delivery | IL-10RB Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling assays. |
View IL10RB Products |
| Benchmark Ab | Anti-IL-10RB Recombinant Antibody Recombinant positive control derived from benchmark clinical sequences. |
View IL10RB Products |
| Validator | IL-10RB siRNA Set For target knockdown verification and specificity controls. |
View IL10RB Products |
| Related Target A | IL-10RA Primary high-affinity receptor subunit; forms the functional IL-10 signaling complex with IL-10RB. |
View IL10RA Products |
| Related Target B | IL-22RA1 Partner receptor subunit; pairs with IL-10RB to mediate IL-22-induced epithelial barrier inflammatory cascades. |
View IL22RA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, Mouse, and Cynomolgus IL-10RB recombinant proteins available with high purity (>95% by SDS-PAGE) to support cross-reactivity screening. |
| Shared subunit off-target screening | Homolog and partner receptor panel (IL-10RA, IL-22RA1, IL-20RA, IFNLR1) strictly verified by mass spectrometry to evaluate binding selectivity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to establish assay baselines. |
| False Positives | Validated siRNA sets included for sequence-specific knockdown verification in cell-based assays. |
Live IL-10RB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-10RB therapeutics is intensifying, with major players shifting focus from systemic cytokine administration to targeted monoclonal antibodies and bispecific formats. As a shared receptor subunit for IL-10, IL-22, IL-26, and type III interferons (IFN-lambdas), IL-10RB represents a critical node in both immunosuppressive and pro-inflammatory pathways. The next wave of R&D is targeting the selective blockade of specific cytokine complexes (such as IL-22/IL-10RB) in inflammatory bowel disease (IBD) and solid tumors, while sparing homeostatic IL-10 signaling to prevent systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Pfizer, Roche, Merck | Inflammatory Bowel Disease (IBD), Autoimmune Disorders | Ligand-blocking assays (Requires high-purity ECD-Fc proteins to block IL-10 or IL-22 binding). |
| Bispecific Antibody | Biotech Innovators | Colorectal Cancer, Solid Tumors | Heterodimer validation (Requires cross-reactive IL-10RB and IL-22RA1/IL-10RA dual-antigen binding assays). |
| Lentiviral Overexpression | Academic & Clinical Labs | Immune-Oncology Microenvironment Studies | Stable cell line construction (Requires Lentiviral Premade Particles for robust STAT3 phosphorylation assays). |